PhRMA Warns of Unforeseen Consequences of Listing Prices in Drug Ads

Drug Industry Daily
A A
The administration’s proposal to require disclosure of list prices for drugs could hurt Medicare and Medicaid beneficiaries, PhRMA claimed in a 30-page comment on CMS’ proposed rule.

To View This Article:

Login

Subscribe To Drug Industry Daily